Samyuktha et al. have also reported that a longer survival rate was observed in those patients who carry the mutant-type gene of CYP1A1 in imatinib treated chronic myeloid leukemia patients (Lakkireddy et al., 2015). The gene discussed is CYP1A1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.